|
|
Primary Myelofibrosis
Alternate Names : Agnogenic Myeloid Metaplasia, Idiopathic Myelofibrosis, Myelofibrosis, Myeloid Metaplasia
Primary Myelofibrosis Prognosis (Expectations)
The average survival of people with primary myelofibrosis is about 5 years. However, many people survive for decades. In the end stages, myelofibrosis is a wasting, debilitating illness.
Today's Top News Stories | • | 2 Techniques Found Effective in Carotid Artery Narrowing - Sep 06, 2008, 09:00
Angioplasty with stenting and endarterectomy successful in preventing ipsilateral stroke. | • | MRIs Don't Improve Breast Cancer Care, Outcome - Sep 06, 2008, 19:00
Study finds getting one delays treatment, raises odds of mastectomy. | • | FDA to List Drugs Under Review for Safety Issues - Sep 05, 2008, 14:00
But officials say patients taking meds on Web site shouldn't overreact or stop taking them. | • | No Place Safe From Allergies - Sep 05, 2008, 16:00
Most can be controlled, but you need to know what triggers them, experts say. | • | Almost Half of Adults Will Develop Knee Osteoarthritis by 85 - Sep 05, 2008, 14:00
Study finds risk is greatest for those overweight or obese at age 45. |
|
Jump to another section
• Definition
• Primary Myelofibrosis Overview, Causes, & Risk Factors
• Primary Myelofibrosis Symptoms & Signs
• Primary Myelofibrosis Prevention
• Primary Myelofibrosis Diagnosis & Tests
• Primary Myelofibrosis Treatment
• Primary Myelofibrosis Prognosis
• Primary Myelofibrosis Complications
• Calling Your Health Care Provider
Topics that might be of interest to you Diseases & Conditions
• Acute Myelogenous Leukemia (AML) - Adult
• Anemia
Tests & Exams
• Bone Marrow Biopsy
• CBC
• Erythropoietin
• Platelet Count
• RBC Count
• WBC Count
Surgery & Procedures
• Spleen Removal
Other Topics
• Bleeding Into the Skin
• Bone Pain or Tenderness
• Breathing Difficulty
• Chemotherapy
• Gas/Flatus - Excessive
• Hepatomegaly
• Jaundice - Yellow Skin
• Paleness
• Splenomegaly
Review Date : 7/31/2003
Reviewed By : Corey Cutler, M.D., M.P.H., F.R.C.P.C., Department of Medical Oncology, Dana-Farber Cancer Institute; Instructor of Medicine, Harvard University, Boston, MA. Review provided by VeriMed Healthcare Network.
|
|
